Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Double-blind, Randomized, Two-stage, Placebo-controlled Proof of Concept Study in Colorectal Cancer Patients Receiving 5-FU Based Chemotherapy to Assess the Efficacy of Elsiglutide (ZP1846)Administered s.c. in the Prevention of Chemotherapy Induced Diarrhea(CID)

NCT01543451 is registered in ClinicalTrials.gov with Helsinn Healthcare SA as lead sponsor.

NCT NCT01543451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01543451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Double-blind, Randomized, Two-stage, Placebo-controlled Proof of Concept Study in Colorectal Cancer Patients Receiving 5-FU Based Chemotherapy to Assess the Efficacy of Elsiglutide (ZP1846)Administered s.c. in the Prevention of Chemotherapy Induced Diarrhea(CID)
Lead sponsor
Helsinn Healthcare SA
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2012
Completion date
October 31, 2013
Enrollment
138 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhea